About the Product
Genetic Labs Tirzepatide is a high-purity synthetic peptide (research grade) supplied in a vial containing 20mg of lyophilized (freeze-dried) powder. It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This unique combination makes it a valuable tool for research in metabolism, endocrinology, and neuroscience.
Kit Contents:
-
1 Vial with 20mg Tirzepatide (Lyophilized Powder)
-
1 Vial with 3mL Bacteriostatic Water (Diluent)
For Laboratory Research Use Only. Not for human consumption.
Benefits (Research Scope)
-
Dual Agonism: Its simultaneous action on both GIP and GLP-1 receptors allows researchers to study the synergistic impact on glycemic control, appetite regulation, and body weight, going beyond the effects of selective GLP-1 agonists alone.
-
Versatile Research Tool: Suitable for a wide range of studies, including:
-
Metabolic Diseases: Research into type 2 diabetes, obesity, and metabolic syndrome.
-
Neuroprotection: Studies on potential neuroprotective effects in neurodegenerative diseases, particularly through improving neuronal insulin resistance.
-
Cardiovascular Health: Investigation of effects on cardiac function, lipid profiles, and blood pressure in models of heart failure and atherosclerosis.
-
Hepatic Diseases: Modeling and study of metabolic dysfunction-associated fatty liver disease (MAFLD).
-
-
Practical Formulation: The lyophilized powder ensures stability and extended shelf life, while the included bacteriostatic water facilitates easy reconstitution for both in vitro and in vivo experiments.
Research & Science
Tirzepatide is currently one of the most extensively studied compounds in the field of metabolic disorders. Its scientific foundation is robust, supported by multiple clinical trials (such as the SURPASS and SURMOUNT programs) and numerous preclinical studies validating its mechanism of action.
-
Mechanism of Action: Its 39-amino-acid structure has been specifically engineered to bind and activate both GIP and GLP-1 receptors with unique potency. Studies suggest that its biased agonism at the GLP-1 receptor (favoring the cAMP signaling pathway) may result in superior insulin secretion compared to selective GLP-1 agonists.
-
Efficacy in Studies: Research has demonstrated that Tirzepatide promotes significant weight reduction (up to 20.9% in clinical trials) and marked improvements in glycemic control, with additional benefits observed in renal and cardiovascular function.
-
Focus on Genetic Variability: Current research is actively exploring how genetic polymorphisms (variations) in receptors such as GIPR and GLP-1R, or in obesity-associated genes like FTO, may influence individual responses to this compound. This is a growing field of pharmacogenomics, crucial for the future development of personalized medicine approaches.
Important Note: This product is strictly for laboratory research purposes only. Its safety and efficacy in humans have not been evaluated by regulatory authorities in this context. It is not intended for diagnostic, therapeutic, or clinical use.